CLYM
$7.12
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibod...
Recent News
Climb Bio Highlights Budoprutug and CLYM116 Milestones, Sets Up “Rich Data Year” in 2026
Climb Bio (NASDAQ:CLYM) used a presentation at the Leerink Partners Global Healthcare Conference to outline its strategy around two immune-focused programs and to preview a series of data readouts expected in 2026. Chief Executive Officer Aoife Brennan and Chief Financial Officer Susan Altschuller d
Climb Bio Highlights 2025 Data Catalysts, CD19 and APRIL Programs at Oppenheimer Conference
Climb Bio (NASDAQ:CLYM) outlined its strategy and upcoming clinical milestones during a fireside chat at Oppenheimer’s 36th Annual Healthcare Life Sciences Conference, with Chief Medical Officer Edgar Charles and CFO Susan Altschuller joining analyst Leland Gershell. Management said the company is
Climb Bio Teases 5 Data Readouts in 2026, Highlights CD19 and APRIL “Sweeper” Programs at Summit
Climb Bio (NASDAQ:CLYM) outlined a slate of near-term clinical milestones and its broader autoimmune disease strategy during a fireside chat at the Guggenheim Emerging Outlook Biotech Summit 2026, with Chief Financial Officer Susan Altschuller and Chief Business Officer Perrin Wilson highlighting fi
Climb Bio, Inc. (NASDAQ:CLYM) Shares Could Be 45% Below Their Intrinsic Value Estimate
Key Insights The projected fair value for Climb Bio is US$9.09 based on 2 Stage Free Cash Flow to Equity Climb Bio's...
H.C. Wainwright Forecasts 2026 Data Readouts for Climb Bio’s (CLYM) Budoprutug Across Clinical Tracks
Climb Bio Inc. (NASDAQ:CLYM) is one of the best biotech penny stocks to buy according to analysts. On December 18, H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Climb Bio to $11 from $9, while maintaining a Buy rating on the shares. This sentiment was announced as the firm believes that Budoprutug’s […]